Moloney Securities Asset Management LLC Has $6.03 Million Stake in Johnson & Johnson (NYSE:JNJ)

Moloney Securities Asset Management LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 16.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 48,412 shares of the company’s stock after buying an additional 6,925 shares during the period. Johnson & Johnson comprises about 3.1% of Moloney Securities Asset Management LLC’s holdings, making the stock its largest position. Moloney Securities Asset Management LLC’s holdings in Johnson & Johnson were worth $6,030,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the stock. Norges Bank acquired a new stake in Johnson & Johnson during the fourth quarter valued at approximately $3,220,322,000. Asset Management One Co. Ltd. boosted its stake in shares of Johnson & Johnson by 1,147.4% in the fourth quarter. Asset Management One Co. Ltd. now owns 4,946,229 shares of the company’s stock worth $569,967,000 after buying an additional 4,549,711 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth about $277,294,000. Renaissance Technologies LLC boosted its stake in shares of Johnson & Johnson by 132.1% in the fourth quarter. Renaissance Technologies LLC now owns 3,423,100 shares of the company’s stock worth $394,375,000 after buying an additional 1,948,000 shares during the last quarter. Finally, Elkfork Partners LLC purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth about $114,861,000. Institutional investors own 66.10% of the company’s stock.

Johnson & Johnson (JNJ) traded down 0.31% on Friday, hitting $132.63. The stock had a trading volume of 4,792,761 shares. The firm has a market cap of $355.98 billion, a P/E ratio of 22.44 and a beta of 0.78. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $137.08. The firm’s 50-day moving average price is $132.88 and its 200-day moving average price is $127.04.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, beating the Zacks’ consensus estimate of $1.79 by $0.04. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The company had revenue of $18.84 billion during the quarter, compared to analysts’ expectations of $18.94 billion. During the same period in the prior year, the company earned $1.74 EPS. Johnson & Johnson’s revenue was up 1.9% compared to the same quarter last year. On average, equities research analysts predict that Johnson & Johnson will post $7.18 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Investors of record on Tuesday, August 29th will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 2.53%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 56.76%.

ILLEGAL ACTIVITY WARNING: “Moloney Securities Asset Management LLC Has $6.03 Million Stake in Johnson & Johnson (NYSE:JNJ)” was published by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.com-unik.info/2017/08/19/johnson-johnson-nysejnj-is-moloney-securities-asset-management-llcs-largest-position-updated-updated-updated.html.

JNJ has been the subject of a number of research reports. BidaskClub upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 17th. Jefferies Group LLC reiterated a “hold” rating and set a $135.00 target price (down previously from $140.00) on shares of Johnson & Johnson in a report on Sunday, May 14th. Royal Bank Of Canada restated a “buy” rating and issued a $128.00 price target on shares of Johnson & Johnson in a report on Thursday, June 15th. Atlantic Securities cut Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 price target for the company. in a report on Friday, July 21st. Finally, Morgan Stanley upped their price target on Johnson & Johnson from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Wednesday, July 5th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the stock. Johnson & Johnson has an average rating of “Hold” and an average price target of $134.12.

In other news, VP Dominic J. Caruso sold 82,591 shares of the firm’s stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the sale, the vice president now directly owns 226,693 shares in the company, valued at approximately $30,993,466.96. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Paulus Stoffels sold 102,692 shares of the firm’s stock in a transaction dated Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the sale, the vice president now owns 230,342 shares of the company’s stock, valued at $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

What are top analysts saying about Johnson & Johnson? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Johnson & Johnson and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit